These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37540652)

  • 1. [Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
    Atonal-Flores B; León-Vázquez ML; Barranco-Juarez A
    Rev Med Inst Mex Seguro Soc; 2023 Jul; 61(4):489-495. PubMed ID: 37540652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
    Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
    Ferrario MG; Lizán L; Montagnoli R; Ramírez de Arellano A
    Prim Care Diabetes; 2016 Jun; 10(3):220-6. PubMed ID: 26546244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
    Bailey TS; Takács R; Tinahones FJ; Rao PV; Tsoukas GM; Thomsen AB; Kaltoft MS; Maislos M
    Diabetes Obes Metab; 2016 Dec; 18(12):1191-1198. PubMed ID: 27381275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
    ; Nathan DM; Lachin JM; Balasubramanyam A; Burch HB; Buse JB; Butera NM; Cohen RM; Crandall JP; Kahn SE; Krause-Steinrauf H; Larkin ME; Rasouli N; Tiktin M; Wexler DJ; Younes N
    N Engl J Med; 2022 Sep; 387(12):1063-1074. PubMed ID: 36129996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
    Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials.
    Keshavarz K; Lotfi F; Sanati E; Salesi M; Hashemi-Meshkini A; Jafari M; Mojahedian MM; Najafi B; Nikfar S
    Daru; 2017 Oct; 25(1):23. PubMed ID: 29070077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
    Wu S; He Y; Wu Y; Ji Y; Hou L; Liu X; Ge Y; Yu Y; Yu Y; Wei Y; Qian F; Luo Q; Feng Y; Feng Y; Wang J; Huo M; Li H; Xue F; Liu Y
    Front Endocrinol (Lausanne); 2022; 13():897776. PubMed ID: 36034458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
    Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
    Pratley R; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Garber A; Thomsen AB; Hartvig H; Davies M;
    Int J Clin Pract; 2011 Apr; 65(4):397-407. PubMed ID: 21355967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
    Moses RG; Round E; Shentu Y; Golm GT; O'neill EA; Gantz I; Engel SS; Kaufman KD; Goldstein BJ
    J Diabetes; 2016 Sep; 8(5):701-11. PubMed ID: 26625270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
    Sharma M; Beckley N; Nazareth I; Petersen I
    BMJ Open; 2017 Oct; 7(10):e017260. PubMed ID: 29084794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
    Brown K; Donato AA
    Ann Intern Med; 2023 Jan; 176(1):JC8. PubMed ID: 36592465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
    Li M; Yang Y; Jiang D; Ying M; Wang Y; Zhao R
    Medicine (Baltimore); 2017 Sep; 96(39):e8161. PubMed ID: 28953663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
    García Díaz E; Guagnozzi D; Gutiérrez V; Mendoza C; Maza C; Larrañaga Y; Perdomo D; Godoy T; Taleb G
    Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
    Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.